A mystery Chinese investor ventured $30 million on San Diego-based BioAtla, which is developing early stage biologics activated in select microenvironments. In a release, BioAtla noted potential applications in monoclonal antibodies, bispecific antibodies, antibody drug conjugates, immune checkpoint inhibitors and CAR-T cells. The company, however, is no stranger to China, with operations in Beijing aimed at bringing along candidates through early clinical work. Release